Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

One pill to tackle two problems: diabetes and cholesterol

NCT ID NCT04602754

First seen Jan 06, 2026 · Last updated Jun 22, 2026 · Updated 26 times

Summary

This Phase 3 trial tests a new combination pill called Berlim 25/20 for people with type 2 diabetes and high cholesterol. The study aims to see if the pill lowers blood sugar and bad cholesterol better than current treatments. About 228 adults will take part, and researchers will also monitor for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIA ASSOCIATED WITH TYPE II DIABETES MELLITUS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Allergisa

    RECRUITING

    Campinas, São Paulo, Brazil

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Berlim 25/20 (a combination of empagliflozin and rosuvastatin)

What this could lead to

If successful, this could offer a single-pill option to manage both blood sugar and cholesterol in people with type 2 diabetes.

What could go wrong

This is a Phase 3 trial, so results are not yet confirmed. The benefits may not apply to all patients, and side effects are possible.

Conditions

The condition(s) this trial relates to.

Dyslipidemias type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.